Hyponatremia in Patients With Nocturnal Enuresis Treated With DDAVP

Robson, Wm. Lane M.; Norgaard, J. P.; Leung, Anthony

doi:10.1097/00005392-199806000-00203

Cited by 9 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Weinstein et al (15) report four cases of clinically significant hyponatraemia in children with underlying coagulopathies given prophylactic DDAVP before surgery in combination with the IV infusion of hypotonic solutions. In contrast with the case that we report, their cases each received multiple doses (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22) of DDAVP.…”

Section: Discussioncontrasting

confidence: 62%

See 1 more Smart Citation

Convulsions and respiratory arrest in association with desmopressin administration for the treatment of a bleeding tonsil in a child with borderline haemophilia

Francis

Leary

Niblett

1999

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 62%

“…Robson et al (5) carried out a meta-analysis of the available literature. They identified 14 articles that reported data on the serum sodium in patients during treatment with DDAVP (a total of 529 patients).…”

Section: Discussionmentioning

confidence: 99%

Convulsions and respiratory arrest in association with desmopressin administration for the treatment of a bleeding tonsil in a child with borderline haemophilia

Francis

Leary

Niblett

1999

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

show abstract

“…At much higher dosages desmopressin is also used in the treatment of bleeding disorders. The primary potential adverse effect associated with desmopressin is water intoxication (Robson et al 1996;Jackson 2001).…”

Section: Introductionmentioning

confidence: 99%

A pharmacokinetic and pharmacodynamic study of desmopressin: evaluating sex differences and the effect of pre-treatment with piroxicam, and further validation of an indirect response model

Odeberg

Callréus

Lundin

et al. 2004

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Desmopressin is a synthetic vasopressin analogue mainly used in treatment of diabetes insipidus and nocturia. Studies in rats have revealed a sex difference in the response to a vasopressin infusion, which was diminished after treatment with an NSAID. This study was performed in man to investigate the influence of sex and concomitant treatment of piroxicam on the pharmacokinetics and dynamics of desmopressin, and to validate a previously described indirect response model. Eight healthy males and eight healthy females participated in the trial, which was conducted in a pharmacokinetic (PK) part followed by a pharmacodynamic (PD) part. Desmopressin was administered intravenously as a single dose (PK = dose 2 microg, PD = dose 0.2 microg). Piroxicam was administered to achieve steady state. The pharmacokinetic parameters of desmopressin were estimated and calculated by means of two-compartmental analysis. In the dynamic part a study design based on an oral hydration model was used. Parameters for urine flow and urine osmolality were estimated. Individual estimates of the pharmacokinetic parameters served as input to the indirect response model that subsequently was fitted to urine osmolality data. The pharmacokinetics of desmopressin after a fixed bolus injection was neither influenced by piroxicam nor sex of the subject. The pharmacodynamics of desmopressin showed a sex difference where females exhibited a more pronounced antidiuretic effect than males, which was statistically significant when the effects were submaximal (>4.5 h after dose). The sex differences were diminished after pre-treatment with piroxicam, indicating a prostaglandin PGE(2)-mediated mechanism. The indirect response model was confirmed, although the modelling could not distinguish a sex difference, indicating a limitation of this model compared with traditional descriptive statistics.

show abstract

“…However, this too may partly be explained by the design of the study, as desmopressin was taken for 7 days (of the 10‐day duration) and placebo for only 3 days. Whilst there is a documented risk of water retention and hyponatraemia using desmopressin therapy [10,11] there were no reported problems in the present study. The present safety variables included serum sodium and creatinine levels at trial entry, serial body weight, and advice about fluid intake fluid.…”

Section: Discussionmentioning

confidence: 60%

Antidiuresis: a new concept in managing female daytime urinary incontinence

et al. 2004

View full text Add to dashboard Cite

bedtime. Secondary efficacy variables included the time to first void or incontinence episode, volume leaked per incontinence episode, total volume voided and number of periods with no leakage. All measurements were made over 7 days on desmopressin and 3 days on placebo. RESULTSThere was a higher mean ( SD ) incidence of periods with no leakage in the first 4 h on desmopressin, at 62 (35)%, than on placebo, at 48 (40)%, and during the first 8 h, at 55 (37)% vs 40 (41)%. There was also a higher frequency of dry days on desmopressin than on placebo; 36% of patients had no leakage on virtually all treatment days (6 or 7) for 4 h after dosing. At 4-8 h the incidence of periods with no leakage on desmopressin was 68 (35)% vs 63 (41)% on placebo, and thereafter the incidence was similar. The time from dosing to first incontinence episode was longer on desmopressin, at 6.3 (2.5) h, vs 5.2 (3.3) h, whilst the volume leaked per incontinence episode was lower on desmopressin than placebo. The total volume voided was consistently lower on desmopressin, at 1180 (58) mL vs 1375 (57) mL, over the 24-h period after administration. There were no serious or severe adverse events reported. Seven women (11%) withdrew from the study, of whom five did not attend for the final visit and two (3%) because of mild adverse events. CONCLUSIONSThe results of this exploratory study suggest that desmopressin is an effective and safe treatment in women with daytime urinary incontinence, and allows them to choose when they need treatment, thus improving motivation, which may aid compliance with therapy. KEYWORDS urinary incontinence, desmopressin, daytime, women OBJECTIVETo investigate the efficacy of desmopressin nasal spray on daytime urinary incontinence in women. PATIENTS AND METHODSA multicentre, multinational, randomized, double-blind, placebo-controlled, cross-over exploratory study of women (aged 18-80 years) complaining of severe daytime urinary incontinence was conducted in three centres (King's College Hospital; Boras County Hospital and Skejby Hospital). Seventy-five patients were screened of whom 64 were randomized. In all, 60 women received study medication (safety population) and 57 completed the study. The intention-to-treat population comprised 59 patients and there were 41 in the per protocol analysis. The primary efficacy endpoint was the number of periods with no leakage for 4 h after dosing. Women were instructed to take the drug at a time of their choosing, but ≥ 4 h before

show abstract

Hyponatremia in Patients With Nocturnal Enuresis Treated With DDAVP

Cited by 9 publications

References 0 publications

Convulsions and respiratory arrest in association with desmopressin administration for the treatment of a bleeding tonsil in a child with borderline haemophilia

Convulsions and respiratory arrest in association with desmopressin administration for the treatment of a bleeding tonsil in a child with borderline haemophilia

A pharmacokinetic and pharmacodynamic study of desmopressin: evaluating sex differences and the effect of pre-treatment with piroxicam, and further validation of an indirect response model

Antidiuresis: a new concept in managing female daytime urinary incontinence

Contact Info

Product

Resources

About